Cited by 300Diabetes Treatment and ManagementRegulation of Appetite and ObesityAdipokines, Inflammation, and Metabolic Diseases

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Effect of Metformin on Glucagon-Like Peptide 1 (GLP-1) and Leptin Levels in Obese Nondiabetic Subjects

Open access

Mannucci, Edoardo, Ognibene, Agostino, Cremasco, Francesco, Bardini, Gianluca, Mencucci, Antonella, Pierazzuoli, Enrica, Ciani, Silvia, Messeri, Gianni, Rotella, Carlo M.·2001·Diabetes Care

DOI 10.2337/diacare.24.3.489

Open this paper in CoChat — free account

Abstract

OBJECTIVE—To evaluate the effects of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels. RESEARCH DESIGN AND METHODS—A total of 10 obese nondiabetic male patients were studied before and after a 14-day treatment with 2,550 mg/day metformin and were compared with 10 untreated obese control subjects. On days 0 and 15, leptin and GLP-1(7–36)amide/(7–37) levels were assessed before and after an oral glucose load during a euglycemic hyperinsulinemic clamp to avoid the interference of variations of insulinemia and glycemia on GLP-1 and leptin secretion. The effects of metformin on GLP-1(7–36)amide degradation in human plasma and in a buffer solution containing dipeptidyl peptidase IV (DPP-IV) were also studied. RESULTS—Leptin levels were not affected by the oral glucose load, and they were not modified after metformin treatment. Metformin induced a significant (P < 0.05) increase of GLP-1(7–36)amide/(7–37) at 30 and 60 min after the oral glucose load (63.8 ± 29.0 vs. 50.3 ± 15.6 pmol/l and 75.8 ± 35.4 vs. 46.9 ± 20.0 pmol/l, respectively), without affecting baseline GLP-1 levels. No variations of GLP-1 levels were observed in the control group. In pooled human plasma, metformin (0.1–0.5 μg/ml) significantly inhibited degradation of GLP-1(7–36)amide after a 30-min incubation at 37°C; similar results were obtained in a buffer solution containing DPP-IV. CONCLUSIONS—Metformin significantly increases GLP-1 levels after an oral glucose load in obese nondiabetic subjects; this effect could be due to an inhibition of GLP-1 degradation.

Integrity signals

Registry

Crossref · 10.2337/diacare.24.3.489

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 916
Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M.-B., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diabetes.44.9.1126 · Cited by 878
Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients
Herrmann, C., Göke, R., Richter, G., Fehmann, H.-C., Arnold, R., & Göke, B. (2009) · Digestion · doi:10.1159/000201231 · Cited by 597
Biguanides and NIDDM
Bailey, C. J. (1992) · Diabetes Care · doi:10.2337/diacare.15.6.755 · Cited by 593
Glucagon-like peptide-1: a potent regulator of food intake in humans
Gutzwiller, J.-P., Göke, B., Drewe, J., Hildebrand, P., Ketterer, S., Handschin, D., Winterhalder, R., Conen, D., & Beglinger, C. (1999) · Gut · doi:10.1136/gut.44.1.81 · Cited by 577
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst, J. J., & Deacon, C. F. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1663 · Cited by 487
Metformin Decreases Food Consumption and Induces Weight Loss in Subjects with Obesity with Type II Non‐Insulin‐Dependent Diabetes
Lee, A., & Morley, J. E. (1998) · Obesity Research · doi:10.1002/j.1550-8528.1998.tb00314.x · Cited by 320
Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus
Mäkimattila, S., Nikkilä, K., & Yki‐Järvinen, H. (1999) · Diabetologia · doi:10.1007/s001250051172 · Cited by 314

Flagged first, then by citations

Show all 26 references

Sorted by citations

Items 101–200 of 297

Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: Nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1
Duffy, N. A., Green, B. D., Irwin, N., Gault, V. A., McKillop, A. M., O'Harte, F. P. M., & Flatt, P. R. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.05.010 · Cited by 50
Combination therapy of dipeptidyl peptidase‐4 inhibitors and metformin in type 2 diabetes: rationale and evidence
Liu, Y., & Hong, T. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12128 · Cited by 49
Dpp4 Inhibitor Sitagliptin As A Potential Treatment Option In Metformin-Intolerant Obese Women With Polycystic Ovary Syndrome: A Pilot Randomized Study
Ferjan, S., Janež, A., & Jensterle, M. (2017) · Endocrine Practice · doi:10.4158/ep-2017-0027 · Cited by 50
Novel Biological Action of the Dipeptidylpeptidase-IV Inhibitor, Sitagliptin, as a Glucagon-Like Peptide-1 Secretagogue
Sangle, G. V., Lauffer, L. M., Grieco, A. J., Trivedi, S., Iakoubov, R., & Brubaker, P. L. (2011) · Endocrinology · doi:10.1210/en.2011-1732 · Cited by 47
The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial
Dore, F. J., Domingues, C. C., Ahmadi, N., Kundu, N., Kropotova, Y., Houston, S., Rouphael, C., Mammadova, A., Witkin, L., Khiyami, A. M., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0709-9 · Cited by 49
Anti‐inflammatory effects of linagliptin in hemodialysis patients with diabetes
Nakamura, Y., Tsuji, M., Hasegawa, H., Kimura, K., Fujita, K., Inoue, M., Shimizu, T., Gotoh, H., Goto, Y., Inagaki, M., et al. (2014) · Hemodialysis International · doi:10.1111/hdi.12127 · Cited by 46
Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study
Lim, S. K., An, J. H., Shin, H., Khang, A. R., Lee, Y., Ahn, H. Y., Yoon, J. W., Kang, S. M., Choi, S. H., Cho, Y. M., et al. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04240.x · Cited by 46
An RCT of metformin versus orlistat for the management of obese anovulatory women
Metwally, M., Amer, S. A. K. S., Li, T. C., & Ledger, W. J. (2008) · Human Reproduction · doi:10.1093/humrep/den454 · Cited by 46
Prescription of oral hypoglycemic agents for patients with type 2 diabetes mellitus: A retrospective cohort study using a Japanese hospital database
Tanabe, M., Motonaga, R., Terawaki, Y., Nomiyama, T., & Yanase, T. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12567 · Cited by 45
Insulin Dynamics Predict Body Mass Index and Z-Score Response to Insulin Suppression or Sensitization Pharmacotherapy in Obese Children
Lustig, R. H., Mietus‐Snyder, M., Bacchetti, P., Lazar, A., Velasquez‐Mieyer, P., & Christensen, M. L. (2006) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2005.08.075 · Cited by 46
Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells
Pala, L., Pezzatini, A., Dicembrini, I., Ciani, S., Gelmini, S., Vannelli, B., Cresci, B., Mannucci, E., & Rotella, C. M. (2010) · Acta Diabetologica · doi:10.1007/s00592-010-0195-3 · Cited by 45
Self-citation
Effect of Metformin on Different Non-Diabetes Related Conditions, a Special Focus on Malignant Conditions: Review of Literature
Abdelgadir, E., Ali, R., Rashid, F., & Bashier, A. M. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2922e · Cited by 45
Investigation of the effect of oral metformin on dipeptidylpeptidase‐4 (DPP‐4) activity in Type 2 diabetes1
Cuthbertson, J., Patterson, S., O'Harte, F. P. M., & Bell, P. M. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02748.x · Cited by 44
Effects of high-fat diet and the anti-diabetic drug metformin on circulating GLP-1 and the relative number of intestinal L-cells
Krizhanovskii, C., Zhang, Q., Nyström, T., & Sjöholm, Å. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-70 · Cited by 44
Effects of chronic treatment with metformin on dipeptidyl peptidase‐4 activity, glucagon‐like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus
Thondam, S. K., Cross, A., Cuthbertson, D. J., Wilding, J. P. H., & Daousi, C. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03675.x · Cited by 43
Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial
Awal, H. B., Nandula, S. R., Domingues, C. C., Dore, F. J., Kundu, N., Břicháček, B., Fakhri, M., Elzarki, A., Ahmadi, N., Safai, S., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01046-z · Cited by 43
New combination treatments in the management of diabetes: focus on sitagliptin – metformin
Green, J. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3105 · Cited by 43
Single-Dose Metformin Enhances Bile Acid–Induced Glucagon-Like Peptide-1 Secretion in Patients With Type 2 Diabetes
Brønden, A., Albèr, A., Rohde, U., Rehfeld, J. F., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01091 · Cited by 43
Metformin: an old drug with new potential
Hajjar, J., Habra, M. A., & Naing, A. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.833604 · Cited by 42
Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo‐controlled 54‐week trial in patients with type 2 diabetes (一项为期54周的对持续使用二甲双胍与罗格列酮联合治疗的2型糖尿病患者加用西格列汀治疗的有效性与安全性的随机安慰剂对照研究)*
Dobs, A. S., Goldstein, B. J., Aschner, P. J., Horton, E. S., Umpierrez, G. E., DURAN, L., HILL, J. S., Chen, Y., Golm, G. T., Langdon, R. B., et al. (2012) · Journal of Diabetes · doi:10.1111/j.1753-0407.2012.00223.x · Cited by 41
Metformin, but not pioglitazone, decreases postchallenge plasma ghrelin levels in type 2 diabetic patients: a possible role in weight stability?
Kusaka, I., Nagasaka, S., Horie, H., & Ishibashi, S. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00857.x · Cited by 40
Effect of initial combination therapy with sitagliptin and metformin on β ‐cell function in patients with type 2 diabetes
Williams‐Herman, D., Xu, L., Teng, R., Golm, G. T., JOHNSON, J. R., Davies, M. J., Kaufman, K. D., & Goldstein, B. J. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01492.x · Cited by 39
Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes
Bianchi, C., Daniele, G., Dardano, A., Miccoli, R., & Prato, S. D. (2017) · Drugs · doi:10.1007/s40265-017-0694-4 · Cited by 41
The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3)
SAIS Study Group, Kitao, N., Miyoshi, H., Furumoto, T., Ono, K., Nomoto, H., Miya, A., Yamamoto, K., Inoue, A., Tsuchida, K., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0607-6 · Cited by 38
TAK ‐875, a GPR 40/ FFAR 1 agonist, in combination with metformin prevents progression of diabetes and β ‐cell dysfunction in Z ucker diabetic fatty rats
Ito, R., Tsujihata, Y., Matsuda‐Nagasumi, K., Mori, I., Negoro, N., & Takeuchi, K. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12297 · Cited by 36
Management and Treatment of Diabetes Mellitus
Imam, K. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5441-0_26 · Cited by 35
Efficacy of Metformin and Topiramate in Prevention and Treatment of Second-Generation Antipsychotic–Induced Weight Gain
Ellinger, L. K., Ipema, H. J., & Stachnik, J. M. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1m550 · Cited by 35
Bariatric surgery – time to replace with GLP-1?
Webb, D., Abrahamsson, N., Sundbom, M., & Hellström, P. M. (2017) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2017.1293154 · Cited by 38
Dipeptidyl Peptidase-4 as a New Target of Action for Type 2 Diabetes Mellitus: A Systematic Review
Wani, J. H., John‐Kalarickal, J., & Fonseca, V. A. (2008) · Cardiology Clinics · doi:10.1016/j.ccl.2008.06.008 · Cited by 35
Fixed-Dose Combination Therapy in Type 2 Diabetes Mellitus
Blonde, L., Juan, Z. T. S., & Bolton, P. (2014) · Endocrine Practice · doi:10.4158/ep14259.ra · Cited by 34
Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes
Maggs, D. G., Macdonald, I. A., & Nauck, M. A. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00737.x · Cited by 34
Cholecystokinin-Induced Gallbladder Emptying and Metformin Elicit Additive Glucagon-Like Peptide-1 Responses
Rohde, U., Sonne, D. P., Christensen, M., Hansen, M., Brønden, A., Toräng, S., Rehfeld, J. F., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1133 · Cited by 33
Neuropeptide Y Overexpressing Female and Male Mice Show Divergent Metabolic but Not Gut Microbial Responses to Prenatal Metformin Exposure
Salomäki-Myftari, H., Vähätalo, L. H., Ailanen, L., Pietilä, S., Laiho, A., Hänninen, A., Pursiheimo, J.-P., Munukka, E., Rintala, A., Savontaus, E., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163805 · Cited by 33
Metformin increases fasting plasma peptide tyrosine tyrosine (PYY) in women with polycystic ovarian syndrome (PCOS)
Tsilchorozidou, T., Batterham, R. L., & Conway, G. S. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03285.x · Cited by 34
Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview
Davidson, J. A., & Sloan, L. A. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0434-2 · Cited by 32
Immunoregulatory Intestinal Microbiota and COVID-19 in Patients with Type Two Diabetes: A Double-Edged Sword
Petakh, P., Kamyshna, I. I., Nykyforuk, A., Yao, R., Imbery, J. F., Oksenych, V., Korda, M. M., & Kamyshnyi, O. (2022) · Viruses · doi:10.3390/v14030477 · Cited by 33
Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin
Scheen, A. J. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.513699 · Cited by 32
Complementing Insulin Therapy to Achieve Glycemic Control
Barnett, A. H. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0039-y · Cited by 33
Obesity Related Alterations in Plasma Cytokines and Metabolic Hormones in Chimpanzees
Nehete, P. N., Magden, E. R., Nehete, B. N., Hanley, P. W., & Abee, C. R. (2014) · International Journal of Inflammation · doi:10.1155/2014/856749 · Cited by 33
Glycaemic goals in patients with type 2 diabetes: current status, challenges and recent advances
Khunti, K., & Davies, M. J. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01186.x · Cited by 31
Glucagon-like peptide 1 (GLP-1) and metabolic diseases
Rotella, C. M., Pala, L., & Mannucci, E. (2005) · Journal of Endocrinological Investigation · doi:10.1007/bf03347560 · Cited by 31
Self-citation
Long-Term Effects of Alogliptin Benzoate in Hemodialysis Patients with Diabetes: A 2-year Study
Nakamura, Y., Inagaki, M., Shimizu, T., Fujita, K., Inoue, M., Gotoh, H., Oguchi, K., & Goto, Y. (2013) · Nephron Clinical Practice · doi:10.1159/000351678 · Cited by 30
Drug evaluation: Vildagliptin-metformin single-tablet combination
Tahrani, A. A., Piya, M. K., & Barnett, A. H. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0010-0 · Cited by 30
Metformin decreases meal size and number and increases c-Fos expression in the nucleus tractus solitarius of obese mice
Kim, H. J., Zhang, X.-H., Park, E.-Y., Shin, K.-H., Choi, S.-H., Chun, B., & Kim, D. H. (2013) · Physiology & Behavior · doi:10.1016/j.physbeh.2013.01.011 · Cited by 31
Potential Role of Phytochemicals as Glucagon-like Peptide 1 Receptor (GLP-1R) Agonists in the Treatment of Diabetes Mellitus
Abiola, J. O., Oluyemi, A. A., Idowu, O. T., Oyinloye, O. M., Ubah, C. S., Owolabi, O. V., Somade, O. T., Onikanni, S. A., Ajiboye, B. O., Osunsanmi, F. O., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17060736 · Cited by 35
Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
Srivastava, S., Saxena, G. N., Keshwani, P., & Gupta, R. (2012) · PubMed · Cited by 29
Combination therapy for type 2 diabetes: dapagliflozin plus metformin
Tan, X., & Hu, J. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1121235 · Cited by 30
Of mice and men: Is there a future for metformin in the treatment of hepatic steatosis?
Green, C., Marjot, T., Tomlinson, J., & Hodson, L. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13592 · Cited by 29
Ezetimibe Stimulates Intestinal Glucagon-Like Peptide 1 Secretion Via the MEK/ERK Pathway Rather Than Dipeptidyl Peptidase 4 Inhibition
Chang, E., Kim, L., Choi, J. M., Park, S. E., Rhee, E., Lee, W., Oh, K.-W., Park, S., Park, D. I., & Park, C. (2015) · Metabolism · doi:10.1016/j.metabol.2015.02.001 · Cited by 29
Antidiabetic medications and weight gain: Implications for the practicing physician
McFarlane, S. I. (2009) · Current Diabetes Reports · doi:10.1007/s11892-009-0040-7 · Cited by 28
Combination of Linagliptin and Metformin for the Treatment of Patients with Type 2 Diabetes
Haak, T. (2015) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.4137/cmed.s10360 · Cited by 28
Evidence for Involvement of GIP and GLP-1 Receptors and the Gut-Gonadal Axis in Regulating Female Reproductive Function in Mice
Khan, D., Ojo, O. O., Woodward, O. R. M., Lewis, J. E., Sridhar, A., Gribble, F. M., Reimann, F. M., Flatt, P. R., & Moffett, R. C. (2022) · Biomolecules · doi:10.3390/biom12121736 · Cited by 31
In support of an early polypharmacy approach to the treatment of type 2 diabetes
Wright, E. E., Stonehouse, A. H., & Cuddihy, R. M. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01255.x · Cited by 27
Obesity, Metabolic Syndrome and Disorders of Energy Balance
Han, J. C., & Weiss, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-62520-3.00024-5 · Cited by 27
Pharmacological characterization of the antidiabetic drug metformin in atherosclerosis inhibition: A comprehensive insight
Turkistani, A. A., Al‐kuraishy, H. M., Al-Gareeb, A. I., Alexiou, A. T., Papadakis, M., Bahaa, M. M., Al‐Windy, S., & Batiha, G. E. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.1346 · Cited by 26
The antidiabetic gutsy role of metformin uncovered?
Burcelin, R. (2013) · Gut · doi:10.1136/gutjnl-2013-305370 · Cited by 26
Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double‐blind placebo‐controlled Phase 3 study in mainland China, Taiwan, and Hong Kong
Pan, C., Han, P., Ji, Q., Li, C., Lu, J., Yang, J., Li, W., Zeng, J., Hsieh, A., & Chan, J. C. N. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12425 · Cited by 26
Effect of oral contraceptives and/or metformin on GLP-1 secretion and reactive hypoglycaemia in polycystic ovary syndrome
Glintborg, D., Mumm, H., Holst, J. J., & Andersen, M. (2017) · Endocrine Connections · doi:10.1530/ec-17-0034 · Cited by 28
Vildagliptin, a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin
Forst, T. M., & Bramlage, P. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.920009 · Cited by 25
Tissue expression of DPP-IV in obesity-diabetes and modulatory effects on peptide regulation of insulin secretion
McKillop, A. M., Stevenson, C. L., Moran, B. M., Abdel‐Wahab, Y. H. A., & Flatt, P. R. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.020 · Cited by 25
Metformin Stimulates Intestinal Glycolysis and Lactate Release: A single‐Dose Study of Metformin in Patients With Intrahepatic Portosystemic Stent
Rittig, N. F., Aagaard, N. K., Sundelin, E. I. O., Villadsen, G. E., Sandahl, T. D., Holst, J. J., Hartmann, B., Brøsen, K., Grønbæk, H., & Jessen, N. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2382 · Cited by 28
Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes
Raskin, P. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00907.x · Cited by 24
From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy
Dicembrini, I., Pala, L., & Rotella, C. M. (2011) · Experimental Diabetes Research · doi:10.1155/2011/898913 · Cited by 24
Self-citation
Reduced plasma levels of glucagon-like peptide-1 in elderly men are associated with impaired glucose tolerance but not with coronary heart disease
Nathanson, D., Zethelius, B., Berne, C., Holst, J. J., Sjöholm, Å., & Nyström, T. (2009) · Diabetologia · doi:10.1007/s00125-009-1596-0 · Cited by 24
Effect of sitagliptin plus metformin on β-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats
Han, S. J., Choi, S., KANG, Y. Y., Jung, J. G., Yi, S., Kim, H. J., Lee, K. W., & Kim, D. J. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.01.016 · Cited by 24
Insulin sensitizers improve the GLP-1 secretion and the amount of intestinal L cells on high-fat-diet–induced catch-up growth
Zheng, J., Xiao, K., Chen, L., Wu, C., Hu, X., Zeng, T., Chen, X.-Q., Li, W., Deng, X., Li, H., et al. (2017) · Nutrition · doi:10.1016/j.nut.2017.01.002 · Cited by 24
MARCH2: Comparative Assessment of Therapeutic Effects of Acarbose and Metformin in Newly Diagnosed Type 2 Diabetes Patients
Wang, G., Liu, J., Yang, N., Gao, X., Fan, H. J., Xu, Y., & Yang, W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105698 · Cited by 23
Effects of metformin and alogliptin on body composition in people with type 2 diabetes
Takeshita, Y., Kita, Y., Kato, K., Kanamori, T., Misu, H., Kaneko, S., & Takamura, T. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12920 · Cited by 23
Effects of Aerobic Exercise with or without Metformin on Plasma Incretins in Type 2 Diabetes
Eshghi, S. R. T., Bell, G. J., & Boulé, N. G. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.030 · Cited by 22
Gluco-Metabolic Effects of Pharmacotherapy-Induced Modulation of Bile Acid Physiology
Brønden, A., & Knop, F. K. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz025 · Cited by 21
A Physiologic and Pharmacological Basis for Implementation of Incretin Hormones in the Treatment of Type 2 Diabetes Mellitus
Freeman, J. S. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0467 · Cited by 21
Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes
Davidson, J. A., Parente, E. B., & Gross, J. L. (2008) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302008000600016 · Cited by 21
Weight gain associated with antidiabetic medications
Provilus, A., Abdallah, M., & McFarlane, S. I. (2011) · Therapy · doi:10.2217/thy.11.8 · Cited by 20
The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy
Tai, H., Wang, M., Yue-ping, Z., Li, L., Dong, Q.-Y., Liu, X., & Jin-song, K. (2016) · Medicine · doi:10.1097/md.0000000000004541 · Cited by 21
The desert gerbil Psammomys obesus as a model for metformin-sensitive nutritional type 2 diabetes to protect hepatocellular metabolic damage: Impact of mitochondrial redox state
Gouaref, I., Détaille, D., Wiernsperger, N. F., Khan, N. A., Leverve, X. M., & Koceir, E.-A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172053 · Cited by 21
Gut-Brain Neuropeptides in the Regulation of Ingestive Behaviors and Obesity.
Crowell, M. D., Decker, G. A., Levy, R. L., Jeffrey, R., & Talley, N. J. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00832.x · Cited by 21
Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus
Guarino, E., Nigi, L., Patti, A., Fondelli, C., & Dotta, F. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.667078 · Cited by 19
CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine
Siskind, D. J., Friend, N., Russell, A. W., McGrath, J. J., Lim, C. C. W., Patterson, S., Flaws, D., STEDMAN, T. J., Moudgil, V., Sardinha, S., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-021000 · Cited by 19
Multifactorial effects of vildagliptin added to ongoing metformin therapy in patients with type 2 diabetes mellitus
Strózik, A., Stęposz, A., Basiak, M., Drożdż, M., & Okopień, B. (2014) · Pharmacological Reports · doi:10.1016/j.pharep.2014.07.016 · Cited by 19
Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation
McKillop, A. M., Duffy, N. A., Lindsay, J. R., Green, B. D., Patterson, S., O'Harte, F. P. M., Bell, P. M., & Flatt, P. R. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0547 · Cited by 18
Evolving Metformin Treatment Strategies in Type-2 Diabetes
Chacra, A. R. (2012) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e318235f1bb · Cited by 20
Pharmacotherapy in the Management of Pediatric Obesity
Kelly, A. S., & Fox, C. K. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0886-z · Cited by 18
Creation of Straight-Chain Cationic Polysaccharide-Based Bile Salt Sequestrants Made from Euglenoid β-1,3-Glucan as Potential Antidiabetic Agents
Shibakami, M., Shibata, K., Akashi, A., Onaka, N., Takezaki, J., Tsubouchi, G., & Yoshikawa, H. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2553-8 · Cited by 18
Molecular mechanisms of lipoapoptosis and metformin protection in GLP-1 secreting cells
Krizhanovskii, C., Holst, J. J., Zhang, Q., & Sjöholm, Å. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.09.010 · Cited by 18
Acute oral metformin enhances satiation and activates brainstem nesfatinergic neurons
Rouquet, T., Clément, P., Gaigé, S., Tardivel, C., Roux, J., Dallaporta, M., Bariohay, B., Troadec, J., & Lebrun, B. (2014) · Obesity · doi:10.1002/oby.20902 · Cited by 18
Disorders of Energy Balance
Lustig, R. H., & Weiss, R. (2008) · Elsevier eBooks · doi:10.1016/b978-141604090-3.50024-7 · Cited by 17
Reversal of insulin resistance by Ficus benghalensis bark in fructose-induced insulin-resistant rats
Khanal, P., & Patil, B. M. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114761 · Cited by 17
Safety and Efficacy of Sitagliptin-Metformin in Fixed Combination for the Treatment of Type 2 Diabetes Mellitus
Ballav, C., & Gough, S. C. L. (2013) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.4137/cmed.s7314 · Cited by 18
Janumet™: a combination product suitable for use in patients with Type 2 diabetes
Reynolds, J. K., Neumiller, J. J., & Campbell, R. K. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.10.1559 · Cited by 16
Retracted: Vitamin D3 potentiates the nephroprotective effects of metformin in a rat model of metabolic syndrome: role of AMPK/SIRT1 activation and DPP-4 inhibition
Wahba, N. S., Ghareib, S. A., Abdel-Ghany, R. H., Abdel-Aal, M., & Alsemeh, A. E. (2020) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2020-0435 · Cited by 16
Retracted
Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
Ved, P., & Shah, S. (2012) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.94258 · Cited by 14
Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation
Scheen, A. J. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.767892 · Cited by 14
The role of MicroRNA networks in tissue-specific direct and indirect effects of metformin and its application
Yang, Q., Wang, G., Fang, D., Gao, X., Yu, L., Wang, L., Wu, J., Zeng, M., & Luo, M. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113130 · Cited by 14
Inhibition of dipeptidyl peptidase-IV (DPP-IV) by atorvastatin
Taldone, T., Zito, S. W., & Talele, T. T. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.11.107 · Cited by 13
Citrus flavonoid supplement enhances glycemic and metabolic control in prediabetic patients on metformin: a randomized controlled trial
Cesar, T. B., de Oliveira, M. R. M., Sandrim, V. C., Mendes, A., Bruder, R., de Oliveira, R. A. A., Sivieri, K., & Milenković, D. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1639901 · Cited by 16
IUPHAR review: From gut to brain: The role of gut dysbiosis, bacterial amyloids, and metabolic disease in Alzheimer’s disease
Inan, S., Wilson, R. P., & Tükel, Ç. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107693 · Cited by 15
Metformin in the Treatment of Obese Children and Adolescents at Risk of Type 2 Diabetes
Kendall, D., Amin, R., & Clayton, P. (2013) · Pediatric Drugs · doi:10.1007/s40272-013-0045-1 · Cited by 13
Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes
Liu, J., Hu, Y., Xu, Y., Jia, Y., Li, M., & Wang, G. (2017) · International Journal of Endocrinology · doi:10.1155/2017/9401606 · Cited by 13
Chemosensing in enteroendocrine cells: mechanisms and therapeutic opportunities
Yang, M. H., Reimann, F. M., & Gribble, F. M. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000614 · Cited by 13
Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus—Part 1
Yandrapalli, S., Jolly, G. P., Horblitt, A. M., Pemmasani, G., Sanaani, A., Aronow, W. S., & Frishman, W. H. (2020) · Cardiology in Review · doi:10.1097/crd.0000000000000308 · Cited by 12

Authors: Mannucci, E., Ognibene, A., Cremasco, F., Bardini, G., Mencucci, A., Pierazzuoli, E., Ciani, S., Messeri, G., & Rotella, C. M.
Affiliations: University of Florence (IT)
Azienda Ospedaliero-Universitaria Careggi (IT)
Corresponding author: Rotella, Carlo M.
ORCID: Mannucci, Edoardo
Ognibene, Agostino
Messeri, Gianni
Rotella, Carlo M.
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2001-03-01
Volume: 24
Issue: 3
Pages: 489-494
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/diacare.24.3.489
OpenAlex: W2157841460
Cited by: 300
References: 26
Citations by year: 2026: 5 · 2025: 6 · 2024: 11 · 2023: 6 · 2022: 10 · 2021: 8 · 2020: 6 · 2019: 11 · 2018: 17 · 2017: 20 · 2016: 24 · 2015: 12 · 2014: 14 · 2013: 26 · 2012: 18
FWCI: 3.46
Type: journal article
Language: en
Open access: green
www.openaccessrepository.it
Licence: other-oa
Locations: Diabetes Care (publishedVersion)
PubMed (publishedVersion)
Florence Research (University of Florence) (submittedVersion)
INFM-OAR (INFN Catania) (submittedVersion, other-oa)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords: metformin, glucagon-like peptide-1, leptin, obesity, GLP-1(7-36)amide, dipeptidyl peptidase IV, oral glucose load, hyperinsulinemic-euglycemic clamp, incretin secretion
MeSH terms: Adolescent, Adult, Blood Glucose, Glucagon-Like Peptides, Glucagon, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Obesity, Peptide Fragments, Peptides, Glucose Clamp Technique, Leptin, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of Metformin on Glucagon-Like Peptide 1 (GLP-1) and Leptin Levels in Obese Nondiabetic Subjects

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks